AUTHORS
Matthew Warrick, PharmD, BCPS, BCOP, Bernard Lawrence Marini Jr, PharmD, BCOP, FHOPA2, Anthony John Perissinotti, PharmD, BCOP3, Dale Lee Bixby, MD, PhD4, Patrick W. Burke, MD5, Kristen Pettit, MD6, Alexander Coltoff, MD7
AFFILIATIONS
1 Medical University of South Carolina, Charleston, South Carolina, United States
2 University of Michigan Health, Ann Arbor, Michigan, United States
3 University of Michigan Health, Ann Arbor, Michigan, United States
4 University of Michigan Health, Ann Arbor, Michigan, United States
5 University of Michigan Health, Ann Arbor, Michigan, United States
6 University of Michigan Health, Ann Arbor, Michigan, United States
7 Medical University of South Carolina, Charleston, South Carolina, United States
ABSTRACT
Background
Acute leukemias of mixed or ambiguous lineage (ALAL) are biologically diverse hematologic malignancies that account for <5% of all acute leukemia. ALAL is associated with an unfavorable prognosis due to phenotypic and genotypic heterogeneity, its rarity, and lack of a standardized treatment approach. Controversy exists over whether utilizing traditional AML, ALL, or hybrid AML/ALL-targeted regimens is most appropriate. FLAG-VIPeR (Reid, et al. Leuk Res 2021) was developed as a hybrid chemotherapy regimen and demonstrated favorable outcomes in a small, single-center study. Further utilization of FLAG-VIPeR following initial publication at a second large academic medical center now provides an updated cohort in which to re-evaluate this promising, novel approach for newly diagnosed ALAL. The objective of this multicenter, retrospective cohort study was to evaluate the safety and efficacy of the FLAG-VIPeR regimen in an expanded cohort of patients with ALAL.
Methods
A retrospective study at two US academic centers was performed. Adults (> 18 years) with a diagnosis of ALAL per WHO 2022 criteria who received induction therapy with FLAG-VIPeR were screened for inclusion. Patients with incomplete records or those treated with alternative treatment strategies were all excluded. FLAG-VIPeR treatment consisted of fludarabine 30 mg/m2 intravenously (IV) days 1-4, cytarabine 2 g/m2 IV days 1-4 (4 hours after completion of fludarabine), granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg/day subcutaneously starting on day 1, vincristine 1.4 mg/m2 (2 mg dose cap) IV on days 1, 8, 15, +/- 22, idarubicin 8-12 mg/m2 days 2-4, prednisone 60 mg/m2 orally days 1-21, and rituximab 375 mg/m2 IV on days 8 and 15 if CD20 positive. The duration of corticosteroids and idarubicin dosing were adjusted based on patient age and comorbidities. The primary endpoint was rate of complete remission or complete remission with incomplete count recovery (CR/CRi). Secondary endpoints included overall survival (OS), event-free survival (EFS), measurable residual disease (MRD) negativity rates, and safety outcomes.
Results
Twenty-seven patients were included in this retrospective cohort study. Median age was 59 years (range, 21-77 years), 37% were female, 19% were non-white/Caucasian, and 56% had ECOG status of 0-1. The immunophenotype was B/myeloid in 48%, T/myeloid in 44%, and B/T/myeloid in 7%. Extramedullary disease was present in 19% of patients, 78% had adverse risk disease per ELN 2022 AML criteria, and 56% had a complex karyotype (>3 unrelated chromosomal abnormalities). Mutations in DNMT3A (29%), FLT3-ITD (28%), FLT3-TKD (28%), TP53 (21%), WT1 (17%), RUNX1 (17%), and N/K/HRAS (17%) were the most common molecular alterations. The rate of CR/CRi rate was 89% (85% CR), and the rate of post-induction MRD negativity via flow cytometry (<1x10-4) was 76% for patients in remission who had testing performed. Among those who achieved a response after induction, 75% received consolidation (median 1 cycle); the majority of consolidations (89%) consisted of at least one cycle of FLAG-VP +/- rituximab. Allogeneic hematopoietic cell transplantation (AlloHCT) was performed in 74% of patients in first remission.
With a median follow up of 21 months, the median OS and EFS were not reached. The estimated 3-year OS was 54.5% (95% CI, 32.7 - 76.3%) and 3-year EFS was 49.4% (95% CI, 28.6 - 79.2%). Five patients relapsed: one without alloHCT 3 months after induction, and four relapsed post-alloHCT (median 15 months post-transplant). The median time to neutrophil recovery (>1000/uL) and platelet recovery (>100,000/uL) were 22 and 22.5 days, respectively, consistent with prior FLAG-VIPeR data. The median duration of hospitalization from the start of FLAG-VIPeR was 26 days (range 18-38 days). Rates of febrile neutropenia, bacteremia, and intensive care unit admission were 85%, 15%, and 15%, respectively. Thirty-day mortality was 3.7%.
Conclusion
This study demonstrates the FLAG-VIPeR hybrid chemotherapy regimen is safe and active in patients with ALAL, resulting in favorable long-term clinical outcomes in a traditionally adverse risk population. These results compare favorably to historic treatment approaches and give further validation to support the use of FLAG-VIPeR as an effective induction. Prospective studies and continued real-world data are needed to refine risk stratification and optimize post-remission management, including timely alloHCT.
DISCLOSURES
Matthew Warrick, PharmD, BCPS, BCOP: No relevant conflicts of interest to declare.